Cargando…

Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin

BACKGROUND: Reduced time in international normalized ratio therapeutic range (TTR) limits warfarin safety and effectiveness. In patients switched from warfarin to direct oral anticoagulants (DOACs), patient factors associated with low TTR could also increase risk of DOAC nonadherence. We investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Pundi, Krishna N., Perino, Alexander C., Fan, Jun, Schmitt, Susan, Kothari, Mitra, Szummer, Karolina, Askari, Mariam, Heidenreich, Paul A., Turakhia, Mintu P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075386/
https://www.ncbi.nlm.nih.gov/pubmed/34779243
http://dx.doi.org/10.1161/JAHA.121.020904
_version_ 1784701671819968512
author Pundi, Krishna N.
Perino, Alexander C.
Fan, Jun
Schmitt, Susan
Kothari, Mitra
Szummer, Karolina
Askari, Mariam
Heidenreich, Paul A.
Turakhia, Mintu P.
author_facet Pundi, Krishna N.
Perino, Alexander C.
Fan, Jun
Schmitt, Susan
Kothari, Mitra
Szummer, Karolina
Askari, Mariam
Heidenreich, Paul A.
Turakhia, Mintu P.
author_sort Pundi, Krishna N.
collection PubMed
description BACKGROUND: Reduced time in international normalized ratio therapeutic range (TTR) limits warfarin safety and effectiveness. In patients switched from warfarin to direct oral anticoagulants (DOACs), patient factors associated with low TTR could also increase risk of DOAC nonadherence. We investigated the relationship between warfarin TTR and DOAC adherence in warfarin‐treated patients with atrial fibrillation switched to DOAC. METHODS AND RESULTS: Using data from the Veterans Health Administration, we identified patients with atrial fibrillation switched from warfarin to DOAC (switchers) or treated with warfarin alone (non‐switchers). Logistic regression was used to evaluate association between warfarin TTR and DOAC adherence. We analyzed 128 605 patients (age, 71±9; 1.6% women; CHA(2)DS(2)‐VASc 3.5±1.6); 32 377 switchers and 96 228 non‐switchers. In 8016 switchers with international normalized ratio data to calculate 180‐day TTR before switch, TTR was low (median 0.45; IQR, 0.26–0.64). Patients with TTR <0.5 were more likely to be switched to DOAC (odds ratio [OR],1.68 [95% CI,1.62–1.74], P<0.0001), as were those with TTR <0.6 or TTR <0.7. Proportion of days covered ≥0.8 was achieved by 76% of switchers at 365 days. In low‐TTR individuals, proportion of days covered ≥0.8 was achieved by 70%, 72%, and 73% of switchers with TTR <0.5, 0.6, and 0.7, respectively. After multivariable adjustment, TTR <0.5 decreased odds of achieving 365‐day proportion of days covered ≥0.8 (OR, 0.49; 0.43–0.57, P<0.0001), with similar relationships for TTR <0.6 and TTR <0.7. In non‐switchers with TTR <0.5, long‐term TTR remained low. CONCLUSIONS: In patients with atrial fibrillation switched from warfarin to DOAC, most achieved adequate DOAC adherence despite low pre‐switch TTRs. However, TTR trajectories remained low in non‐switchers. Patients with low warfarin TTR more consistently achieved treatment targets after switching to DOACs, although adherence‐oriented interventions may be beneficial.
format Online
Article
Text
id pubmed-9075386
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-90753862022-05-10 Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin Pundi, Krishna N. Perino, Alexander C. Fan, Jun Schmitt, Susan Kothari, Mitra Szummer, Karolina Askari, Mariam Heidenreich, Paul A. Turakhia, Mintu P. J Am Heart Assoc Original Research BACKGROUND: Reduced time in international normalized ratio therapeutic range (TTR) limits warfarin safety and effectiveness. In patients switched from warfarin to direct oral anticoagulants (DOACs), patient factors associated with low TTR could also increase risk of DOAC nonadherence. We investigated the relationship between warfarin TTR and DOAC adherence in warfarin‐treated patients with atrial fibrillation switched to DOAC. METHODS AND RESULTS: Using data from the Veterans Health Administration, we identified patients with atrial fibrillation switched from warfarin to DOAC (switchers) or treated with warfarin alone (non‐switchers). Logistic regression was used to evaluate association between warfarin TTR and DOAC adherence. We analyzed 128 605 patients (age, 71±9; 1.6% women; CHA(2)DS(2)‐VASc 3.5±1.6); 32 377 switchers and 96 228 non‐switchers. In 8016 switchers with international normalized ratio data to calculate 180‐day TTR before switch, TTR was low (median 0.45; IQR, 0.26–0.64). Patients with TTR <0.5 were more likely to be switched to DOAC (odds ratio [OR],1.68 [95% CI,1.62–1.74], P<0.0001), as were those with TTR <0.6 or TTR <0.7. Proportion of days covered ≥0.8 was achieved by 76% of switchers at 365 days. In low‐TTR individuals, proportion of days covered ≥0.8 was achieved by 70%, 72%, and 73% of switchers with TTR <0.5, 0.6, and 0.7, respectively. After multivariable adjustment, TTR <0.5 decreased odds of achieving 365‐day proportion of days covered ≥0.8 (OR, 0.49; 0.43–0.57, P<0.0001), with similar relationships for TTR <0.6 and TTR <0.7. In non‐switchers with TTR <0.5, long‐term TTR remained low. CONCLUSIONS: In patients with atrial fibrillation switched from warfarin to DOAC, most achieved adequate DOAC adherence despite low pre‐switch TTRs. However, TTR trajectories remained low in non‐switchers. Patients with low warfarin TTR more consistently achieved treatment targets after switching to DOACs, although adherence‐oriented interventions may be beneficial. John Wiley and Sons Inc. 2021-11-15 /pmc/articles/PMC9075386/ /pubmed/34779243 http://dx.doi.org/10.1161/JAHA.121.020904 Text en © 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Pundi, Krishna N.
Perino, Alexander C.
Fan, Jun
Schmitt, Susan
Kothari, Mitra
Szummer, Karolina
Askari, Mariam
Heidenreich, Paul A.
Turakhia, Mintu P.
Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin
title Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin
title_full Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin
title_fullStr Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin
title_full_unstemmed Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin
title_short Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin
title_sort direct oral anticoagulant adherence of patients with atrial fibrillation transitioned from warfarin
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075386/
https://www.ncbi.nlm.nih.gov/pubmed/34779243
http://dx.doi.org/10.1161/JAHA.121.020904
work_keys_str_mv AT pundikrishnan directoralanticoagulantadherenceofpatientswithatrialfibrillationtransitionedfromwarfarin
AT perinoalexanderc directoralanticoagulantadherenceofpatientswithatrialfibrillationtransitionedfromwarfarin
AT fanjun directoralanticoagulantadherenceofpatientswithatrialfibrillationtransitionedfromwarfarin
AT schmittsusan directoralanticoagulantadherenceofpatientswithatrialfibrillationtransitionedfromwarfarin
AT kotharimitra directoralanticoagulantadherenceofpatientswithatrialfibrillationtransitionedfromwarfarin
AT szummerkarolina directoralanticoagulantadherenceofpatientswithatrialfibrillationtransitionedfromwarfarin
AT askarimariam directoralanticoagulantadherenceofpatientswithatrialfibrillationtransitionedfromwarfarin
AT heidenreichpaula directoralanticoagulantadherenceofpatientswithatrialfibrillationtransitionedfromwarfarin
AT turakhiamintup directoralanticoagulantadherenceofpatientswithatrialfibrillationtransitionedfromwarfarin